Table 2.
Group | n | Treatmenta | Survival times (days) | Mean survival ±SD (days) |
P valueb | Acute rejection |
Chronic rejection |
GVHD |
---|---|---|---|---|---|---|---|---|
IA | 11 | — | 9, 9, 8, 7,7,7,7,7, 7, 6, 6 |
7.3±1.0 | — | 11/11 | 0/11 | 0/11 |
IIA | 10 | FK long course |
131, 118, 96, 38, 36, 33, 25, 13, 9, 7 |
50.6±46.5 | 0.0001 | 0/10c | 5/10c | 0/10 |
III | 8 | FK short course |
76, 73, 63,31, 11, 10, 8, 7 |
34.9±30.8 | 0.0008 | 3/8 | 3/8 | 0/8 |
IV | 9 | ALG (do- nor), FK short course |
79, 40, 25, 21, 11, 8, 7, 5, 5 |
22.3±24.2 | 0.0324 | 5/9 | 2/9 | 0/9 |
V | 11 | CsA 15 long course |
24, 9, 9, 8, 8, 7, 7, 6, 6, 5, 5 |
8.5±5.3 | 0.7441 | 9/11 | 0/11 | 0/11 |
VI | 7 | CsA 20 long course |
23, 13, 11, 10, 9, 7, 5 | 11.1±5.8 | 0.0150 | 7/7 | 0/7 | 0/7 |
VII | 9 | CsA 40 short course |
>114, 69, 28, 27, 26, 16, 15, 8, 6 |
34.3±35.2 | 0.0007 | 4/9 | 1/9 | 0/9 |
Refer to Table 1.
Generalized savage (Mantel-Cox) value comparing survival times to that of untreated controls.
Chi-square, P value <0.05.